Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers
NCT02392637
Completed
This phase II trial studies how well gemcitabine hydrochloride, cisplatin, and nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle formulation) work in treating patients with biliary cancers (which includes the gallbladder and bile ducts inside and outside the liver) that have spread to other places in the body and usually cannot be cured or controlled with treatment. Drugs used in chemotherapy, such as gemcitabine hydrochloride, cisplatin, and paclitaxel albumin-stabilized nanoparticle f... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/05/2022
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona +2 locations
Conditions: Stage III Intrahepatic Cholangiocarcinoma AJCC v7, Stage IIIA Gallbladder Cancer AJCC v7, Stage IIIB Gallbladder Cancer AJCC v7, Stage IVA Gallbladder Cancer AJCC v7, Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7, Stage IVB Gallbladder Cancer AJCC v7, Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7, Unresectable Extrahepatic Bile Duct Carcinoma, Unresectable Gallbladder Carcinoma
Register for Updates
Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
NCT00043108
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving combination chemotherapy with radiation therapy before and after surgery may shrink the tumor so it can be removed during surgery and may kill any remaining tumor cells following surgery. PURPOSE: Phase II trial to study the effectiveness of combining paclitaxel and carboplatin with radiation therapy and s... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
01/05/2022
Locations: Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania
Conditions: Lung Cancer
Register for Updates
Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors
NCT01042522
Unknown
This randomized phase II trial studies paclitaxel and carboplatin to see how well they work compared with bleomycin sulfate, etoposide phosphate, and cisplatin in treating patients with sex cord-ovarian stromal tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or has returned (recurrent). Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from divi... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/30/2021
Locations: Alaska Breast Care and Surgery LLC, Anchorage, Alaska +218 locations
Conditions: Ovarian Granulosa Cell Tumor, Ovarian Gynandroblastoma, Ovarian Sertoli-Leydig Cell Tumor, Ovarian Sex Cord Tumor With Annular Tubules, Ovarian Sex Cord-Stromal Tumor, Ovarian Steroid Cell Tumor, Ovarian Sex Cord-Stromal Tumor, Not Otherwise Specified
Register for Updates
IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery
NCT03029611
Terminated
This phase II trial studies how well pUMVC3-IGFBP2 plasmid deoxyribonucleic acid (DNA) vaccine (IGFBP-2 vaccine) and combination chemotherapy work in treating patients with stage III-IV ovarian, fallopian tube, or primary peritoneal cancer undergoing surgery. IGFBP-2 is a protein found in the blood and tumor cells of most who have been diagnosed with ovarian cancer. Too much IGFBP-2 has been associated with more invasive disease. Vaccines made from DNA may help the body build an effective immune... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/17/2021
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Stage III Fallopian Tube Cancer, Stage III Ovarian Cancer, Stage III Primary Peritoneal Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer
Register for Updates
PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer
NCT03166085
Completed
The purpose of this study is to decide the best dose of the study drug, PU-H71, that can be given in combination with the standard chemotherapy drug, nab-paclitaxel (Abraxane).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/17/2021
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Metastatic Breast Cancer
Register for Updates
A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer
NCT03400306
Withdrawn
This study will evaluate the bioavailability between the veliparib tablet formulation to the capsule formulation; and will assess the effect of food on veliparib bioavailability in participants with ovarian cancer.
Gender:
FEMALE
Ages:
Between 18 years and 99 years
Trial Updated:
12/06/2021
Locations: Lifespan Cancer Institute /ID# 200130, Providence, Rhode Island +1 locations
Conditions: Cancer - Ovarian
Register for Updates
Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC
NCT00960297
Terminated
The rationale for this multicenter, phase II trial is to examine the impact of carboplatin/paclitaxel with bevacizumab in the preoperative treatment of patients with stage IB (\> 4.0 cm), II, and select stage III NSCLC. If this novel regimen proves to be safe and active in this setting, this would provide rationale for further investigation in a larger, prospective, randomized setting.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2021
Locations: Holy Cross Hospital, Fort Lauderdale, Florida +5 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer
NCT00629499
Completed
This is a non-randomized, Phase II study. Efficacy is not a primary endpoint in this study; however, progression-free survival will be followed and determined for the patients in this study. Approximately 50 patients are planned to be enrolled in this study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/23/2021
Locations: Watson Clinic Center for Cancer Care and Research, Lakeland, Florida +9 locations
Conditions: Breast Cancer
Register for Updates
Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer
NCT00193206
Completed
In this trial we will evaluate ABI-007 with gemcitabine and epirubicin, utilizing the biweekly pegfilgrastim support, in order to further improve upon the effectiveness and favorable toxicity of this triplet.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/22/2021
Locations: Florida Cancer Specialists, Fort Myers, Florida +12 locations
Conditions: Breast Cancer
Register for Updates
COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer
NCT04038489
Withdrawn
This study is designed to assess the safety and clinical activity of tamoxifen and the COX inhibitor, aspirin, given in combination with standard AC-T chemotherapy (doxorubicin, cyclophosphamide, and paclitaxel) for the treatment of high-risk estrogen receptor (ER)+, human epidermal growth factor receptor 2 (HER2)- breast cancer. If successful, the study could improve long-term outcomes for a subpopulation of women with aggressive stage I-III ER+/HER2- breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/12/2021
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Breast Cancer, Estrogen Receptor-positive Breast Cancer
Register for Updates
Study of Topical SOR007 Ointment for Cutaneous Metastases
NCT03101358
Completed
This study evaluates a topical nanoparticle paclitaxel ointment (SOR007) for the treatment of cutaneous metastases from non-melanoma cancer in adults. Three concentrations of SOR007 will be evaluated in dose-rising cohorts of three. An expanded cohort will treat additional subjects at the maximum tolerated dose.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/03/2021
Locations: University of Southern California, Los Angeles, California +3 locations
Conditions: Cutaneous Metastasis
Register for Updates
A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer
NCT00660218
Completed
This study involves two phases. Phase I of this study is designed to find out the maximum dose of paclitaxel poliglumex which can be safely given to subjects when combined with cetuximab and radiotherapy in head and neck cancer. Once the maximum safe dose of paclitaxel poliglumex is found, Phase II of the study will continue to find out whether the addition of paclitaxel poliglumex increases tumor response and survival compared to treatment with cetuximab and radiotherapy alone. An additional 2... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/29/2021
Locations: SUNY Upstate Medical University, Syracuse, New York
Conditions: Carcinoma, Squamous Cell
Register for Updates